A structured review of patient-reported outcome measures for patients with skin cancer, 2013

British Journal of Dermatology

Volumn 168, Issue 6, 2013, Pages 1176-1186

  Gibbons, E ^a   Casanas I Comabella C ^a   Fitzpatrick, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER THERAPY; CONSTRUCT VALIDITY; CONTENT VALIDITY; FUNCTIONAL ASSESSMENT; HEALTH IMPACT ASSESSMENT; HEALTH SURVEY; HUMAN; INTERNAL CONSISTENCY; MELANOMA SKIN CANCER; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SELF REPORT; SHORT FORM 36; SKIN CANCER;

HUMANS; MELANOMA; PATIENT OUTCOME ASSESSMENT; PATIENTS; QUALITY OF LIFE; SELF REPORT; SICKNESS IMPACT PROFILE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84878632163     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12310     Document Type: Review

References (40)

1. Darzi A,. Our NHS. Our Future: NHS Next Stage Review Interim Report. London: Department of Health, 2007.
2. Darzi A,. Our NHS. Our Future: High Quality Care for All. NHS Next Stage Review Final Report. London: Department of Health, 2008.
3. Department of Health. The Outcomes Framework: 2013/2014. London: Department of Health, 2012.
4. Department of Health. Improving Outcomes: A Strategy for Cancer. London: Department of Health, 2011.
5. Smith SC, Cano S, Lamping DL, et al,. Patient-Reported Outcome Measures (PROMs) for routine use in Treatment Centres: Recommendations Based on a Review of the Scientific Literature. Final Report to Department of Health. London: Health Services Research Unit, London School of Hygiene & Tropical Medicine, 2005.
6. Fitzpatrick R, Davey C, Buxton M, Jones DR, et al,. Evaluating patientbased outcome measures for use in clinical trials. Health Technol Assess 1998; 2 i-iv: 1-74.
7. Fitzpatrick R, Bowling A, Gibbons E, et al,. A Structured Review of Patient-Reported Measures in Relation to Selected Chronic Conditions, Perceptions of Quality of Care and Carer Impact. Report to the Department of Health. Oxford: National Centre for Health Outcomes Development, 2006.
8. Lee EH, Klassen AF, Nehal KS, et al,. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. J Am Acad Dermatol 2012. Available at: http://www.jaad.org/article/S0190-9622(12)00940-1/abstract (last accessed 12 December 2012).
9. Cormier JN, Askew RL,. Assessment of patient-reported outcomes in patients with melanoma. Surg Oncol Clin N Am 2011; 20: 201-13.
10. Ware JE Jr, Gandek B, Group IP,. The SF-36 Health Survey: development and use in mental health research and the IQOLA Project. Int J Ment Health 1994; 23: 49-73.
11. Ware JE Jr,. SF-36 Health Survey Manual and Interpretation Guide, Vol. 2. Boston, MA: Nimrod Press, 1997.
12. Ware JE Jr, Sherbourne CD, Davies AR,. Developing and testing the MOS 20-Item Short-Form Health Survey: a general population application. In: Measuring Functioning and Well-being: The Medical Outcomes Study Approach (, Stewart AL, Ware JE Jr, eds). Durham, NC: Duke University Press, 1992; 277-90.
13. Bergner M, Bobbitt RA, Pollard WE, et al,. The Sickness Impact Profile: validation of a health status measure. Med Care 1976; 14: 57-67.
14. Bergner M, Bobbitt RA, Carter WB, et al,. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805.
15. Chren MM, Lasek RJ, Quinn LM, et al,. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life patients with skin disease. J Invest Dermatol 1997; 108: 103-7.
16. Rhee JS, Loberiza FR, Matthews BA, et al,. Quality of life assessment in nonmelanoma cervicofacial skin cancer. Laryngoscope 2003; 113: 215-20.
17. Trask PC, Griffith KA,. The identification of empirically derived cancer patient subgroups using psychosocial variables. J Psychosom Res 2004; 57: 287-95.
18. Blanchard CM, Courneya KS, Stein K, et al,. Cancer survivors' adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society's SCS-II. J Clin Oncol 2008; 26: 2198-204.
19. Blackford S, Roberts D, Salek MS, Finlay A,. Basal cell carcinomas cause little handicap. Qual Life Res 1996; 5: 191-4.
20. Aaronson NK, Ahmedzai S, Bergman B, et al,. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
21. Allenby A, Matthews J, Beresford J, et al,. The application of computer touch-screen technology in screening for psychosocial distress in an ambulatory oncology setting. Eur J Cancer Care 2002; 11: 245-53.
22. Dixon S, Walters SJ, Turner L, et al,. Quality of life and cost-effectiveness of interferon-alpha in malignant melanoma: results from randomised trial. Br J Cancer 2006; 94: 492-8.
23. Cella DF, Tulsky DS, Gray G, et al,. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-9.
24. Cormier JN, Davidson L, Xing Y, et al,. Measuring quality of life in patients with melanoma: development of the FACT-melanoma subscale. J Support Oncol 2005; 3: 139-45.
25. Swartz RJ, Baum GP, Askew RL, et al,. Reducing patient burden to the FACT-Melanoma quality-of-life questionnaire. Melanoma Res 2012; 22: 158-63.
26. Cormier JN, Xing Y, Ding M, et al,. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol 2007; 25: 2442-8.
27. Robinson DW Jr, Cormier JN, Zhao N, et al,. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study. Melanoma Res 2012; 22: 54-62.
28. Askew RL, Xing Y, Palmer JL, et al,. Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire. Value Health 2009; 12: 1144-50.
29. Paterson AG, Trask PC, Wagner LI, et al,. Validation of the FACT-BRM with interferon-alpha treated melanoma patients. Qual Life Res 2005; 14: 133-9.
30. Rhee JS, Matthews BA, Neuburg M, et al,. Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plast Surg 2006; 8: 314-18.
31. Rhee JS, Matthews BA, Neuburg M, et al,. The skin cancer index: clinical responsiveness and predictors of quality of life. Laryngoscope 2007; 117: 399-405.
32. Rhee JS, Matthews BA, Neuburg M, et al,. Creation of a quality of life instrument for nonmelanoma skin cancer patients. Laryngoscope 2005; 115: 1178-85.
33. Matthews BA, Rhee JS, Neuburg M, et al,. Development of the facial skin care index: a health-related outcomes index for skin cancer patients. Dermatol Surg 2006; 32: 924-34; discussion 934.
34. Finlay AY, Khan GK,. Dermatology Life Quality Index/DLQI: a simple practical measure for routine clinical use. Clin Exp Rheumatol 1994; 19: 210-16.
35. Rhee JS, Matthews BA, Neuburg M, et al,. Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 2004; 30: 525-9.
36. Shah M, Coates M,. An assessment of the quality of life in older patients with skin disease. Br J Dermatol 2006; 154: 150-3.
37. Chren MM, Lasek RJ, Quinn LM, et al,. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-13.
38. Chren MM, Lasek RJ, Sahay AP, Sands LP,. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg 2001; 5: 105-10.
39. Chren M-M, Sahay AP, Bertenthal DS, et al,. Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2007; 127: 1351-7.
40. Burdon-Jones D, Gibbons K,. The Skin Cancer Quality of Life Impact Tool (SCQOLIT): a validated health-related quality of life questionnaire for non-metastatic skin cancers. J Eur Acad Dermatol Venereol 2012. Available at: http://dx.doi.org/10.1111/j.1468-3083.2012.04669.x (last accessed 26 January 2013).